PMID- 34145459
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20210929
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 224
IP  - 6
DP  - 2021 Sep 17
TI  - Large-Scale Identification of T-Cell Epitopes Derived From Severe Acute 
      Respiratory Syndrome Coronavirus 2 for the Development of Peptide Vaccines 
      Against Coronavirus Disease 2019.
PG  - 956-966
LID - 10.1093/infdis/jiab324 [doi]
AB  - BACKGROUND: Coronavirus disease 2019 (COVID-19) continues to be a major public 
      health challenge globally. The identification of severe acute respiratory 
      syndrome coronavirus 2 (SARS-CoV-2)-derived T-cell epitopes is of critical 
      importance for peptide vaccines or diagnostic tools of COVID-19. METHODS: In this 
      study, several SARS-CoV-2-derived human leukocyte antigen (HLA)-I binding 
      peptides were predicted by NetMHCpan-4.1 and selected by Popcover to achieve 
      pancoverage of the Chinese population. The top 5 ranked peptides derived from 
      each protein of SARS-CoV-2 were then evaluated using peripheral blood mononuclear 
      cells from unexposed individuals (negative for SARS-CoV-2 immunoglobulin G). 
      RESULTS: Seven epitopes derived from 4 SARS-CoV-2 proteins were identified. It is 
      interesting to note that most (5 of 7) of the SARS-CoV-2-derived peptides with 
      predicted affinities for HLA-I molecules were identified as HLA-II-restricted 
      epitopes and induced CD4+ T cell-dependent responses. These results complete 
      missing pieces of pre-existing SARS-CoV-2-specific T cells and suggest that 
      pre-existing T cells targeting all SARS-CoV-2-encoded proteins can be discovered 
      in unexposed populations. CONCLUSIONS: In summary, in the current study, we 
      present an alternative and effective strategy for the identification of T-cell 
      epitopes of SARS-CoV-2 in healthy subjects, which may indicate an important role 
      in the development of peptide vaccines for COVID-19.
CI  - (c) The Author(s) 2021. Published by Oxford University Press for the Infectious 
      Diseases Society of America. All rights reserved. For permissions, e-mail: 
      journals.permissions@oup.com.
FAU - Ma, Yipeng
AU  - Ma Y
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen International Biological Valley-Life Science 
      Industrial Park, Dapeng New District, Shenzhen, China.
FAU - Liu, Fenglan
AU  - Liu F
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen International Biological Valley-Life Science 
      Industrial Park, Dapeng New District, Shenzhen, China.
FAU - Lin, Tong
AU  - Lin T
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen International Biological Valley-Life Science 
      Industrial Park, Dapeng New District, Shenzhen, China.
FAU - Chen, Lei
AU  - Chen L
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen International Biological Valley-Life Science 
      Industrial Park, Dapeng New District, Shenzhen, China.
FAU - Jiang, Aixin
AU  - Jiang A
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen International Biological Valley-Life Science 
      Industrial Park, Dapeng New District, Shenzhen, China.
FAU - Tian, Geng
AU  - Tian G
AD  - Department of Oncology, Shenzhen Second People's Hospital, The First Affiliated 
      Hospital of Shenzhen University, Shenzhen, China.
FAU - Nielsen, Morten
AU  - Nielsen M
AUID- ORCID: 0000-0001-7885-4311
AD  - Department of Health Technology, Section for Bioinformatics, Technical University 
      of Denmark, Lyngby, Denmark.
FAU - Wang, Mingjun
AU  - Wang M
AD  - Department of Research and Development, Shenzhen Institute for Innovation and 
      Translational Medicine, Shenzhen International Biological Valley-Life Science 
      Industrial Park, Dapeng New District, Shenzhen, China.
LA  - eng
GR  - 2020B1515120018/Guangdong Basic and Applied Basic Research Foundation/
GR  - JCYJ20180507182902330/Shenzhen Basic Research Program/
GR  - KQTD20130416114522736/Shenzhen Peacock Plan/
GR  - KJYF202001-13/Special Funds for Dapeng New District Industry Development/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (COVID-19 Vaccines)
RN  - 0 (Epitopes, T-Lymphocyte)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - COVID-19/*immunology/*prevention & control
MH  - COVID-19 Vaccines/*immunology
MH  - Cell Line
MH  - Epitopes, T-Lymphocyte/*immunology
MH  - Humans
MH  - Leukocytes, Mononuclear/immunology
MH  - SARS-CoV-2
MH  - Vaccines, Subunit/*immunology
OTO - NOTNLM
OT  - 2
OT  - CoV
OT  - SARS
OT  - T-cell epitopes
OT  - existing T cells
OT  - pre
OT  - uninfected individuals
EDAT- 2021/06/20 06:00
MHDA- 2021/09/30 06:00
CRDT- 2021/06/19 06:20
PHST- 2021/04/14 00:00 [received]
PHST- 2021/06/16 00:00 [accepted]
PHST- 2021/06/20 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2021/06/19 06:20 [entrez]
AID - 6305142 [pii]
AID - 10.1093/infdis/jiab324 [doi]
PST - ppublish
SO  - J Infect Dis. 2021 Sep 17;224(6):956-966. doi: 10.1093/infdis/jiab324.